Abstract
In 2008, Dutch customs authorities blocked generic medicines in transit in the Dutch territory on suspicion of their being counterfeit. India and Brazil subsequently claimed that external transit control of medicines is inconsistent with the Trade‐Related Aspects of Intellectual Property Rights (TRIPS), the Doha Declaration on TRIPS and Public Health and international provisions on access to medicines. This article aims to shed light on the consistency of external transit control of generics with international law, and on the interrelations between issues of intellectual property, free trade and public health at the international level; it shows that TRIPS makes possible a broad extension of IP rights protection while ceilings present some weaknesses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
